Program
L-(+)-methylenetetrahydrofolic acid
Also written as “Arfolitixorin”, “Modufolin (arfolitixorin)” and “6R-MTHF (arfolitixorin) 200 mg/m2”.
Its studies are mostly in Colorectal Neoplasms · Colonic Neoplasms, led by Isofol Medical AB.
Furthest: phase 3, since Nov 19, 20185 company-led studies, 1 open or runningNext primary completion: Nov 30, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Isofol Medical AB | 51 open or running | phase 3since Nov 19, 2018 | Sep 5, 2012 | Nov 30, 2028phase 2 · NCT06922383 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 5, 2012First study: phase 2 study in Colonic NeoplasmsFirst studyNCT01681472 · 32 enrolled · Sweden
- Sep 17, 2014Phase 2 study in Colorectal NeoplasmsNCT02244632 · 105 enrolled · Denmark, Greece, Norway and more
- Jun 22, 2017Phase 1 study in Phase I Study in Healthy Volunteers to Evaluate ECG EffectNCT03203564 · 33 enrolled · Sweden
- Nov 19, 2018Phase 3 study in Colonic NeoplasmsNCT03750786 · 490 enrolled · United States, Australia, Austria and more
- Mar 25, 2025Phase 2 study in Colorectal NeoplasmsNCT06922383 · 90 planned · Germany
Ahead
- Nov 30, 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT06922383
TargetBeta
HTT →read by rule
“The R-isomer of folitixorin, a reduced folate-based biomodulator and active metabolite of folate drugs leucovorin (LV) and levoleucovorin (l-LV) that can be used to increase the efficacy of certain antimetabolites, such as the cytotoxic agent 5-fluorouracil (5-FU), and reduce as well as protect agai”NCIt, by rule
Other programs on HTT
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06922383Colorectal Neoplasms · Germany | 2 | Recruiting | Nov 30, 2028 | 90 |
| NCT03750786Colonic Neoplasms · United States, Australia, Austria and more | 3 | Completed | Nov 18, 2022 | 490 |
| NCT03203564Phase I Study in Healthy Volunteers to Evaluate ECG Effect · Sweden | 1 | Completed | Aug 25, 2017 | 33 |
| NCT02244632Colorectal Neoplasms · Denmark, Greece, Norway and more | 2 | Completed | Jan 30, 2020 | 105 |
| NCT01681472Colonic Neoplasms · Sweden | 2 | Completed | Aug 2013 | 32 |
How it is read
Names in the registry
- “Arfolitixorin”, 2 entries
- “Modufolin (arfolitixorin)”, 2 entries
- “6R-MTHF (arfolitixorin) 200 mg/m2”, 1 entry
- “6R-MTHF (arfolitixorin) 60 mg/m2”, 1 entry
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 2 studies
- Colonic Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.